KNSA vs ONC: fair value comparison
Kiniksa Pharmaceuticals International, plc and BeOne Medicines AG · Updated 2026-10-19
ONC is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, KNSA currently ranks higher by quality score.
| KNSA | ONC | |
|---|---|---|
| Verdict | Fairly valued | Awaiting full valuation |
| Last price | $78.59 | $369.06 |
| 12-month range | $37.01–$80.92 | $260.27–$377.47 |
| Rank by discount to fair value | #104 of 108 Healthcare | — |
| Rank by quality score | #5 of 301 Healthcare | #6 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: KNSA fair value analysis · ONC fair value analysis